Healthcare [ 7/13 ] | Biotechnology [ 61/159 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 15, 24 | -1.1 Increased by +34.52% | -1.32 Increased by +16.67% |
| Nov 2, 23 | 1.15 Increased by +142.75% | -1.34 Increased by +185.82% |
| Aug 3, 23 | -2.21 Increased by +3.49% | -1.37 Decreased by -61.31% |
| May 4, 23 | -1.4 Increased by +30% | -1.77 Increased by +20.9% |
| Feb 23, 23 | -1.68 Increased by +22.22% | -1.9 Increased by +11.58% |
| Oct 27, 22 | -2.69 Decreased by -64.02% | -1.77 Decreased by -51.98% |
| Jul 28, 22 | -2.29 Decreased by -42.24% | -1.63 Decreased by -40.49% |
| Apr 28, 22 | -2 Decreased by -16.96% | -1.84 Decreased by -8.7% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 439.72 M Increased by +31.25% | -137.87 M Increased by +33.55% | Decreased by -31.35% Increased by +49.37% |
| Sep 30, 23 | 750.53 M Increased by +183.96% | 147.75 M Increased by +136.4% | Increased by +19.69% Increased by +112.82% |
| Jun 30, 23 | 318.75 M Increased by +41.78% | -276.02 M Increased by +0.5% | Decreased by -86.59% Increased by +29.82% |
| Mar 31, 23 | 319.29 M Increased by +49.72% | -174.1 M Increased by +27.56% | Decreased by -54.53% Increased by +51.62% |
| Dec 31, 22 | 335.04 M Increased by +29.59% | -207.49 M Increased by +19.72% | Decreased by -61.93% Increased by +38.05% |
| Sep 30, 22 | 264.31 M Increased by +40.86% | -405.92 M Decreased by -98.48% | Decreased by -153.58% Decreased by -40.9% |
| Jun 30, 22 | 224.82 M Increased by +1.93% | -277.4 M Decreased by -46.34% | Decreased by -123.39% Decreased by -43.56% |
| Mar 31, 22 | 213.26 M Increased by +20.1% | -240.34 M Decreased by -20% | Decreased by -112.7% Increased by +0.09% |
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.